Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00353171 · ClinicalTrials.gov registry record

Organochlorine Exposure in Relation to Timing of Natural Menopause

A clinical trial, sponsored by National Institute of Environmental Health Sciences (NIEHS).

Completed
Registry status
514
Enrollment target

NCT00353171: Completed study, sponsored by National Institute of Environmental Health Sciences (NIEHS).

NCT00353171 is a clinical trial that has completed, run by National Institute of Environmental Health Sciences (NIEHS). The registered enrollment target is 514 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00353171 has completed, sponsored by National Institute of Environmental Health Sciences (NIEHS).

COMPLETED
Registry status
514 participants
Enrollment target

Study Summary

This study will examine whether exposure to organochlorines (certain chemicals such as PCBs and DDE, used in pesticides or other industrial applications) is related to age at natural menopause. It is known, for example, that smokers experience menopause 1 to 2 years earlier than do non-smokers. This study will look for a similar association between organochlorine exposure and menopause. It will also look for possible associations between specific factors, such as pregnancy history and weight change, and changes over time in blood organochlorine levels. Women who participated in the North Carolina Infant Feeding Study between 1978 and 1982 are eligible for this study. Participants will be interviewed over the phone for information about their reproductive and menstrual history, as well as additional information that may be related to age and menopausal status. Specifically, the interview will cover the following areas: 1) pregnancy and breastfeeding history; 2) menstrual periods and menopause; 3) use of birth control pills and hormone replacement therapy; 4) surgeries on the uterus or ovaries, such as hysterectomy or oophorectomy, or both; 5) smoking and alcoholic beverage consumption; 6) physical activity; 7) weight history; and 8) medical history. About one-half of the participants will have a blood sample drawn for analysis of the reproductive hormones FSH (follicle-stimulating hormone) and LH (leuteinizing hormone) and of DDE and PCB levels.

Trial Details

FieldValue
Enrollment Target 514 participants
Start Date 2003-03-01
Est. Completion 2019-05-29

What the finished NCT00353171 record still lists

NCT00353171 is an observational study that tracks outcomes without assigning an intervention. The registered 514 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT00353171 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00353171 about?

NCT00353171 is a clinical study titled "Organochlorine Exposure in Relation to Timing of Natural Menopause". This study will examine whether exposure to organochlorines (certain chemicals such as PCBs and DDE, used in pesticides or other industrial applications) is related to age at natural menopause. It is known, for example, that smokers experience menopause 1 to 2 years earlier than do non-smokers. This...

What is the current status of trial NCT00353171?

This trial is currently completed. The enrollment target is 514 participants. The study started on 2003-03-01. Estimated completion is 2019-05-29.

Who is sponsoring clinical trial NCT00353171?

This trial is sponsored by National Institute of Environmental Health Sciences (NIEHS), which has 145 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05691244 · 514 participants · Phase 3

    Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

  • NCT06585488 · 514 participants · Phase 1

    A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification

  • NCT06716606 · 514 participants · Phase 3

    A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)

  • NCT05577819 · 515 participants · NA

    Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT00353171, the US trial registry maintained by the National Library of Medicine. NCT00353171 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.